Synaptic dysfunction

Synaptic dysfunction, often referred to as synaptopathy, is a pathological state characterized by the impairment of synaptic signaling, structural integrity, and plasticity between neurons (Lepeta et al., 2016, J Neurochem). It is not a single molecular target but rather a complex physiological failure involving multiple proteins, neurotransmitters, and signaling pathways. This phenomenon is a primary driver of cognitive decline and motor deficits in various conditions, including Alzheimer's disease, Parkinson's disease, and schizophrenia (Wishart et al., 2006, BioEssays). Therapeutic strategies often focus on specific molecular components within the synapse, such as receptors or enzymes, to restore functional connectivity. For example, drugs like Donepezil and Memantine are used to mitigate the effects of synaptic failure by modulating neurotransmitter levels (StatPearls, 2023). Biomarkers such as Synaptic Vesicle Protein 2A (SV2A) and Neurogranin are increasingly used in clinical research to quantify synaptic density and monitor disease progression (Finnema et al., 2016, Sci Transl Med). Understanding synaptic dysfunction is crucial for developing interventions that can preserve or repair neural networks before irreversible neuronal death occurs (Johnston, 2004, Nat Rev Neurosci).

Other names

SynaptopathySynaptic failureSynaptic lossImpaired synaptic plasticity

Restoration of neurotransmitter levels, modulation of ion channel activity, and enhancement of synaptic plasticity to compensate for loss of connectivity.